certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-19. Anything still debated is marked as such rather than presented as settled.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
=== Free triiodothyronine === Free triiodothyronine (fT3 or free T3) is generally elevated in hyperthyroidism and decreased in hypothyroidism. Reference ranges depend on the method of analysis. Results should always be interpreted using the range from the laboratory that performed the test. Example values are:
=== Historical use by government agencies === Beginning in the 1950s, the US Central Intelligence Agency (CIA) began a research program code-named Project MKUltra. The CIA introduced LSD to the United States, purchasing the entire world's supply for $240,000 and propagating the LSD through CIA front organizations to American hospitals, clinics, prisons, and research centers. Experiments included administering LSD to CIA employees, military personnel, doctors, other government agents, prostitutes, mentally ill patients, and members of the general public to study their reactions (usually without the subjects' knowledge), the most well-known example of this being Operation Midnight Climax. The project was revealed in the US congressional Rockefeller Commission report in 1975. However, the extent of the experiments conducted under Project MKUltra are still mostly unknown, as acting CIA director Richard Helms destroyed many of the key documents related to MKUltra in 1973. According to declassified CIA documents, it's possible that the American agency spread LSD amongst civilians in Europe in the 1950s. LSD was also one of several psychoactive substances evaluated by the U.S. Army Chemical Corps as possible non-lethal incapacitants in the Edgewood Arsenal human experiments.
Another method of end group removal for the thiocarbonyl containing end-groups of RAFT polymers is the addition of heat to the polymer; this is referred to as thermolysis. One method of monitoring thermolysis of RAFT polymers is by thermogravimetric analysis resulting in a weight-loss of the end group. An advantage of this technique is that no additional chemicals are required to remove the end group; however, it is required that the polymer be thermally stable to high temperature and therefore may not be effective for some polymers. Depending on the polymers sensitivity to ultraviolet radiation (UV) it has been reported in recent years that decomposition of end-groups can be effective, but preliminary data suggest that decomposition by UV leads to a change in the distribution of molecular weights of the polymer.
=== Intravesical instillation === Sodium hyaluronate can be instilled into the bladder for the treatment of various forms of cystitis and associated bladder pain, by replenishing the glycosaminoglycan layer of the bladder urothelium.
Sources: en.wikipedia.org
The brand became a well-established franchise in the Philippines, where it began in 1975 under the ownership of the country's largest food conglomerate, San Miguel Corporation, primarily promoting their San Miguel draft beer. Beginning with a restaurant located on Makati Avenue in Makati, the restaurant expanded rapidly in Metro Manila, with most of its outlets offering live music. San Miguel had difficulty maintaining the consistency of the branches, and ultimately sold the franchise in 1987 to International Family Food Services, Inc. (IFFSI), a group led by the family of sports executive Leo Prieto. In 1997, it had evolved into mostly a fast-food franchise. The brand was reengineered as a family-oriented casual dining brand in 2003. In 2004, Shakey's partnered with Sports Vision for the launch of the Shakey's V-League, one of the pioneering volleyball leagues in the country. The Shakey's Super League was formally launched on August 16, 2022, at the Shakey's Pizza Aseana City outlet in Parañaque. This marks the return of Shakey's Pizza in Philippine volleyball since they served as the title sponsor for the Shakey's V-League (now Premier Volleyball League) from 2004 to 2017. As of early 2015, there were 153 Shakey's outlets in the Philippines, more than double the number remaining in the United States. In March 2016, the Century Pacific Group and the Singapore-based GIC Private Limited acquired the majority shares of IFFSI from the Prieto family, which will retain a minority interest in the company.
=== Clinical trials === As of 2023, an ERAP1 Inhibitor (GRWD5769) developed by Grey Wolf Therapeutics has entered phase I/II. Its safety, tolerability, efficacy, and pharmacokinetics are being evaluated in patients with viral associated solid tumours (head and neck squamous cell carcinoma, cervical cancer, and hepatocellular carcinoma) that are particularly sensitive to ERAP1 inhibition, as monotherapy, or in combination with PD-1 immune checkpoint Inhibitor Libtayo® (cemiplimab).
== Mechanism of action == An average dairy cow begins her lactation with a moderate daily level of milk production. This daily output increases until, at about 70 days into the lactation, production peaks. From that time until the cow is dry, production slowly decreases. This increase and decrease in production is partially caused by the count of milk-producing cells in the udder. Cell counts begin at a moderate number, increase during the first part of the lactation, then decrease as the lactation proceeds. Once lost, these cells generally do not regrow until the next lactation. Administration of rBST or BST prior to peak production, in cows that are well-fed, slows the rate at which the number of mammary cells decreases, and increases the amount of nutrients directed away from fat and toward the mammary cells, leading to an extension of peak milk production. The effects are mediated by the insulin-like growth factor (IGF) system, which is upregulated in response to BST or rBST administration in well-fed cows.
=== Features that promote de novo gene birth === Its also of interest to compare features of recently emerged de novo genes to the pool of non-genic ORFs from which they emerge. Theoretical modeling has shown that such differences are the product both of selection for features that increase the likelihood of functionalization, and of neutral evolutionary forces that influence allelic turnover. In budding yeast, systematic deletion and overexpression assays of newly emerged ORFs found that overexpression is enriched for fitness benefits, and that adaptive emerging sequences are biased toward encoding transmembrane domains from thymine-rich intergenic regions. One proposed route to de novo membrane proteins is that poly-A–rich sequences can generate hydrophobic ORFs that are predicted to form transmembrane helices. Across Saccharomycotina yeasts, intergenic regions show widespread enrichment for putative transmembrane-domain encoding potential, and this enrichment (rather than raw hydrophobicity alone) correlates with the abundance of transmembrane domains in evolutionarily young genes. Laboratory studies comparing young de novo proteins to matched unevolved random-sequence proteins found broadly similar predicted biophysical-property distributions, but moderately higher in vitro solubility for de novo proteins (further increased by the DnaK chaperone system). High-throughput sorting of thousands of putative human de novo sORF-encoded proteins by structural compactness showed that older candidates are, on average, more compact and less disordered than younger ones.
Flaps can be fundamentally classified by their mechanism of movement, the types of tissues present, or by their blood supply. The surgeon generally chooses the least complex type that will achieve the desired effect via a concept known as the reconstructive ladder.
Sources: en.wikipedia.org
== Career and research == Springer then pursued postdoctoral work on antigen-specific T lymphocyte helper factors at the University of Cambridge. Within six months, Springer failed to replicate key experiments and discovered fraudulent work, followed by a retraction. He switched to work under César Milstein at the University of Cambridge and the MRC Laboratory of Molecular Biology, soon after the development of monoclonal antibody technology. Milstein personally taught Springer how to make monoclonal antibodies, and with his first set of hybridomas in hand, Springer returned to the United States after another six months. Before his postdoc, Springer was offered a position as Assistant Professor at Harvard Medical School by Baruj Benacerraf, the Chair of Pathology, and joined that department in 1977. He was recruited to the Dana–Farber Cancer Institute in 1981 after Benacerraf became its President, as Chief of the Laboratory of Membrane Immunochemistry, and was promoted to Associate Professor in 1983. In 1988, Springer was recruited by Fred Rosen to move his lab to and become Vice President of the Center for Blood Research. He was involved in planning its new space in the Warren Alpert Building and recruiting faculty. These included Ulrich von Andrian, Jose Carlos Gutierrez-Ramos, Rick van Etten, Anjana Rao, Denisa Wagner, and Judy Lieberman. Later, he led searches that recruited Sun Hur, Wesley Wong, and Hao Wu. Four of these recruits were subsequently elected to the National Academy of Sciences. Springer became the Latham Family Professor in 1989.
Duke Nukem Forever had been a project with a troubled development history at 3D Realms, who had created the Duke Nukem series, since sometime prior to 2000. Due to financial difficulties in 2009, 3D Realms was forced to downsize and ultimately lay off most of the development staff. Take-Two Interactive sued 3D Realms for failing to deliver Duke Nukem Forever. Pitchford, who had prior industry relations with many 3D Realms staff including George Broussard, learned that many of the 3D Realms team were still eager to develop Duke Nukem Forever, working out of their homes on what they could. Pitchford negotiated with Take-Two to bring many of the former 3D Realms staff into a new studio called Triptych Games, housed at Gearbox's headquarters, to continue working on Duke Nukem Forever following 3D Realms' closure in 2009. As a result, 3D Realms sold the rights to Duke Nukem and the existing work on Duke Nukem Forever to Gearbox around February 2010. Take-Two and Gearbox subsequently announced in September 2010 that Gearbox would finish production of Duke Nukem Forever. Duke Nukem Forever was released in June 2011, and received negative critical reception on release, with most of the criticism directed towards the unfinished, rushed state of the game. Despite the criticism, the game topped the charts on release and made a profit. 3D Realms had initially sued Gearbox in June 2013 for unpaid royalties over Duke Nukem Forever, but dropped the suit by September 2013, with 3D Realms' founder Scott Miller stating that it was a misunderstanding on its part.
(CH2CH2)O + H2S → HO–CH2CH2–HS 2 (CH2CH2)O + H2S → (HO–CH2CH2)2S (CH2CH2)O + RHS → HO–CH2CH2–SR The excess of ethylene oxide with an aqueous solution of hydrogen sulfide leads to the tris-(hydroxyethyl) sulfonyl hydroxide:
These include Faces of Degeneration (CUP, 1989), The Pursuit of the Nazi Mind (OUP, 2012). and Brainwashed: A New History of Thought Control (Profile/Wellcome Collection, 2022) He has written, and taught at London University for many years, on aspects of the history of psychoanalysis and psychiatry, modernism, the relationship of Freudian thought to historiography, Victorian evolutionary theory, eugenics and social Darwinism, ideas of war and peace, fin-de-siècle literature, and the history of cultural attitudes to crime and madness. He is an associate editor of History Workshop Journal. Pick has presented for the BBC, including 'The Unconscious Life of Bombs', BBC Radio 4 (December 2017); 'Dictators on the Couch', BBC Radio 4 (June 2017); and 'Freud for our Times', BBC Radio 4 (December 2016). Harold Pinter, Nobel prize-winning writer, playwright; Pinter signed the mission statement of Jews for Justice for Palestinians in 2005 and its full-page advertisement, "What Is Israel Doing? A Call by Jews in Britain", published in The Times on 6 July 2006, and he was a patron of the Palestine Festival of Literature. In April 2008, Pinter signed the statement "We're not celebrating Israel's anniversary".
The AKUH Clinical Laboratories operate a nationwide network of 300+ specimen collection centres across 100+ cities in Pakistan. AKUH Clinical Laboratories are accredited by the College of American Pathologists (CAP), while the Hospital and Outreach Services are accredited by Joint Commission International (JCI).
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.